



Dr. Arndt Schottelius  
CHIEF DEVELOPMENT OFFICER

Dr. Simon Moroney  
CHIEF EXECUTIVE OFFICER

Dr. Marlies Sproll  
CHIEF SCIENTIFIC OFFICER

Jens Holstein  
CHIEF FINANCIAL OFFICER

# Management Board of MorphoSys AG

---

*“This has been another year of excellent progress for MorphoSys in both partnered and proprietary drug development. Our increasing investment in proprietary R&D is paying off, as is evident from our growing portfolio of therapeutic candidates. As the first product candidates get closer to the market, the huge potential value in our pipeline is becoming more and more tangible.”*

DR. SIMON MORONEY

---

*“Progress with our lead cancer compound MOR208 was very encouraging last year. Very promising clinical data both in CLL and NHL and important regulatory achievements bode well for future development of this compound. With MOR209/ES414 we have been able to add a highly innovative prostate cancer compound to our portfolio.”*

DR. ARNDT SCHOTTELIUS

---

*“Our ability to advance our existing proprietary programs and to drive the expansion of our portfolio continues to be a main strength of our business. With € 353 million in cash and other financial assets MorphoSys has the financial resources to establish a substantial proprietary portfolio on top of our maturing partnered pipeline.”*

JENS HOLSTEIN

---

*“In 2014, our partnered pipeline has matured significantly and now includes more programs in clinical trials and in a more advanced state than ever before. With guselkumab, developed by Janssen/J&J, the third partnered program based on our HuCAL antibody platform entered pivotal trials. Guselkumab joins Novartis’s bimagrumab as a contender for the first HuCAL antibody to enter the market.”*

DR. MARLIES SPROLL